Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 604 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR At 27, She Was Told She Was Too Young For Breast... February 6, 2020 Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm May 20, 2021 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas January 20, 2021 Can Using Essential Oils Help Treat Cancer and Its Side Effects? July 13, 2021 Load more HOT NEWS Cancer Survivor with Strong Family History Was Denied Regular Screening Because... FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type Lung Adenocarcinoma with Mucinous Histology Thanks For Making This GivingTuesday Our Best One Yet!
